Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + Lenvatinib + HAIC for Unresectable HCC
NCT06406634Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- May 2024
- Primary completion
- Apr 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in hepatocellular carcinoma (HCC), sponsored by Hunan Cancer Hospital. Primary endpoint: Objective Response Rate up to 2 years. Started May 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06406634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06406634.